Chengdu Kanghua Biological Products Co., Ltd.

Shenzhen Stock Exchange 300841.SZ

Chengdu Kanghua Biological Products Co., Ltd. Revenue for the year ending December 31, 2023: USD 222.18 M

Chengdu Kanghua Biological Products Co., Ltd. Revenue is USD 222.18 M for the year ending December 31, 2023, a 5.98% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Chengdu Kanghua Biological Products Co., Ltd. Revenue for the year ending December 31, 2022 was USD 209.64 M, a 3.07% change year over year.
Chengdu Kanghua Biological Products Co., Ltd. Revenue for the year ending December 31, 2021 was USD 203.41 M, a 27.83% change year over year.
Chengdu Kanghua Biological Products Co., Ltd. Revenue for the year ending December 31, 2020 was USD 159.12 M, a 99.78% change year over year.
Chengdu Kanghua Biological Products Co., Ltd. Revenue for the year ending December 31, 2019 was USD 79.65 M, a -2.09% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shenzhen Stock Exchange: 300841.SZ

Chengdu Kanghua Biological Products Co., Ltd.

CEO	Mr. Wennian Wu
IPO Date	June 16, 2020
Location	China
Headquarters	No. 182, Beijing Road
Employees	672
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, production, sale, and technical service of biological products in China. It offers group ACYW135 meningococcal polysaccharide vaccines; and freeze-dried human diploid cell rabies vaccines. The company also develops seasonal influenza vaccines without preservatives, which completed phase III clinical trials; and human H5N1 influenza vaccine that completed pre-clinical studies. In addition, it exports its products. The company was founded in 2004 and is based in Chengdu, China.

Key trends

Past 5 years